NOVO NORDISK A S

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.

Sep 30, 2026 · Filed Nov 4, 2026

Use the contents to explore the available documents and sections.

NVO$40.31+0.0%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

APPENDIX 5: ADJUSTED SALES SPLIT PER AREA

Q3 2026 adjusted sales split per area
DKK million · Total · US Operations · International Operations · EUCAN · Emerging Markets · APAC · Region China
Obesity and Diabetes segment
	Wegovy® injectable	20,407	11,066	9,341	5,711	1,777	1,526	327
	% change at CER	(2%)	(13%)	16%	29%	7%	(20%)	184%
	Wegovy® pill	5,394	4,178	1,216	1,094	122	0	0
% change at CER · N/A · N/A · N/A · N/A · N/A · N/A · N/A
	Saxenda®	345	22	323	126	187	11	(1)
	% change at CER	(59%)	(79%)	(56%)	(58%)	(48%)	(80%)	(111%)
	Total Obesity	26,146	15,266	10,880	6,931	2,086	1,537	326
	% change at CER	22%	20%	24%	47%	4%	(22%)	162%
	Injectable GLP-1 diabetes	29,811	19,124	10,687	7,149	1,264	881	1,393
	% change at CER	(7%)	(12%)	4%	22%	(33%)	12%	(22%)
		Ozempic®	29,706	19,205	10,501	7,103	1,260	869	1,269
		% change at CER	(5%)	(11%)	8%	23%	(24%)	18%	(22%)
		Victoza®	105	(81)	186	46	4	12	124
		% change at CER	(83%)	(268%)	(65%)	(63%)	(98%)	(75%)	(18%)
	Ozempic® pill / Rybelsus®	4,938	2,109	2,829	1,385	667	731	46
	% change at CER	(10%)	5%	(19%)	(18%)	39%	(15%)	(89%)
	Total GLP-1 diabetes	34,749	21,233	13,516	8,534	1,931	1,612	1,439
	% change at CER	(7%)	(10%)	(2%)	13%	(18%)	(2%)	(36%)
	Long-acting insulin1	4,379	704	3,675	1,376	886	314	1,099
	% change at CER	1%	(17%)	6%	(10%)	22%	4%	24%
	Premix insulin2	2,419	111	2,308	196	307	519	1,286
	% change at CER	8%	(27%)	10%	(9%)	28%	(1%)	13%
	Fast-acting insulin3	4,379	1,678	2,701	1,244	795	271	391
	% change at CER	7%	(4%)	14%	4%	33%	(5%)	34%
	Human insulin	1,088	296	792	100	394	149	149
	% change at CER	(21%)	(38%)	(11%)	(39%)	(2%)	0%	(15%)
	Total insulin	12,265	2,789	9,476	2,916	2,382	1,253	2,925
	% change at CER	2%	(13%)	8%	(6%)	22%	0%	17%
	Other Diabetes4	531	12	519	116	74	56	273
	% change at CER	18%	(28%)	20%	(9%)	19%	(3%)	53%
	Total Diabetes	47,545	24,034	23,511	11,566	4,387	2,921	4,637
	% change at CER	(5%)	(11%)	2%	7%	2%	(1%)	(6%)
	Obesity and Diabetes total	73,691	39,300	34,391	18,497	6,473	4,458	4,963
	% change at CER	3%	(1%)	8%	19%	3%	(9%)	(1%)
Blood & endocrine disorders segment
	Blood disorders5	3,055	1,277	1,778	807	649	274	48
	% change at CER	3%	9%	(2%)	(2%)	37%	7%	(79%)
	Endocrine disorders6	1,994	1,217	777	306	191	259	21
	% change at CER	43%	51%	33%	20%	89%	19%	267%
	Other blood & endocrine disorders7	455	86	369	254	65	48	2
	% change at CER	8%	30%	4%	2%	34%	(8%)	0%
	Blood & endocrine disorders total	5,504	2,580	2,924	1,367	905	581	71
	% change at CER	15%	27%	6%	3%	45%	11%	(70%)
Total adjusted sales	79,195	41,880	37,315	19,864	7,378	5,039	5,034
	% change in DKK	6%	2%	10%	18%	11%	(8%)	1%
	% change at CER	4%	1%	8%	18%	6%	(7%)	(5%)
	Share of growth	101%	8%	93%	100%	14%	(13%)	(8%)
1) Comprises Tresiba®, Xultophy®, Levemir® and Awiqli®.
2) Comprises Ryzodeg® and NovoMix®.
3) Comprises Fiasp® and NovoRapid®.
4) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.
5) Comprises NovoSeven®, NovoEight®, Esperoct®, Refixia®, NovoThirteen® and Alhemo®.
6) Primarily Norditropin® and Sogroya®.
7) Primarily Vagifem® and Activelle®.

2030 ambitions	Performance highlights	Commercial execution	Financials	Cash flow and capital allocation	Outlook	R&D pipeline progress	Sustainability	Corporate Governance	Legal matters	Financial information

Financial report for the period 1 January 2026 to 30 September 2026	Page 29 of 35

9M 2026 adjusted sales split per area
DKK million · Total · US Operations · InternationalOperations · EUCAN · Emerging Markets · APAC · Region China
Obesity and Diabetes segment
	Wegovy® injectable	58,126	30,195	27,931	16,359	5,726	4,769	1,077
	% change at CER	4%	(15%)	38%	55%	31%	10%	13%
	Wegovy® pill	10,868	9,575	1,293	1,094	199	0	0
% change at CER · N/A · N/A · N/A · N/A · N/A · N/A · N/A
	Saxenda®	1,216	72	1,144	510	588	46	0
	% change at CER	(55%)	(72%)	(54%)	(57%)	(42%)	(80%)	(100%)
	Total Obesity	70,210	39,842	30,368	17,963	6,513	4,815	1,077
	% change at CER	20%	11%	34%	53%	22%	5%	9%
	Injectable GLP-1	89,526	57,393	32,133	21,025	4,225	2,550	4,333
	% change at CER	(5%)	(8%)	3%	23%	(39%)	0%	(10%)
		Ozempic®	88,906	57,473	31,433	20,854	4,093	2,503	3,983
		% change at CER	(3%)	(8%)	8%	26%	(32%)	5%	(8%)
		Victoza®	620	(80)	700	171	132	47	350
		% change at CER	(74%)	(140%)	(67%)	(70%)	(85%)	(68%)	(29%)
	Ozempic® pill / Rybelsus®	14,738	5,966	8,772	4,377	2,021	2,327	47
	% change at CER	(10%)	(6%)	(12%)	(19%)	27%	(4%)	(87%)
	Total GLP-1 diabetes	104,264	63,359	40,905	25,402	6,246	4,877	4,380
	% change at CER	(5%)	(8%)	(1%)	13%	(27%)	(2%)	(18%)
	Long-acting insulin1	13,023	2,316	10,707	4,447	2,440	860	2,960
	% change at CER	(4%)	(27%)	4%	(5%)	6%	(4%)	22%
	Premix insulin2	7,604	310	7,294	619	1,515	1,537	3,623
	% change at CER	(1%)	(18%)	0%	(11%)	2%	6%	0%
	Fast-acting insulin3	13,025	4,953	8,072	3,780	2,406	789	1,097
	% change at CER	(1%)	(11%)	7%	6%	12%	0%	9%
	Human insulin	3,199	928	2,271	313	1,037	444	477
	% change at CER	(21%)	(6%)	(26%)	(39%)	(26%)	(26%)	(13%)
	Total insulin	36,851	8,507	28,344	9,159	7,398	3,630	8,157
	% change at CER	(4%)	(16%)	1%	(3%)	1%	(3%)	7%
	Other Diabetes4	1,795	42	1,753	367	206	183	997
	% change at CER	31%	(55%)	38%	(6%)	3%	(3%)	109%
	Total Diabetes	142,910	71,908	71,002	34,928	13,850	8,690	13,534
	% change at CER	(5%)	(9%)	0%	8%	(14%)	(2%)	0%
	Obesity and Diabetes total	213,120	111,750	101,370	52,891	20,363	13,505	14,611
	% change at CER	2%	(3%)	8%	20%	(5%)	0%	1%
Blood & endocrine disorders segment
	Blood disorders5	8,584	3,573	5,011	2,440	1,601	846	124
	% change at CER	(2%)	(1%)	(2%)	0%	17%	15%	(77%)
	Endocrine disorders6	4,679	2,525	2,154	919	494	704	37
	% change at CER	21%	18%	25%	31%	17%	21%	111%
	Other Blood & endocrine disorders7	1,363	286	1,077	738	194	139	6
	% change at CER	15%	54%	7%	5%	22%	1%	20%
	Blood & endocrine disorders total	14,626	6,384	8,242	4,097	2,289	1,689	167
	% change at CER	6%	7%	5%	6%	17%	16%	(70%)
Total adjusted sales	227,746	118,134	109,612	56,988	22,652	15,194	14,778
	% change in DKK	0%	(6%)	8%	19%	(1%)	(3%)	(1%)
	% change at CER	2%	(2%)	8%	19%	(3%)	2%	(2%)
	Share of growth	100%	(55%)	155%	170%	(15%)	5%	(5%)
1) Comprises Tresiba®, Xultophy®, Levemir® and Awiqli®.
2) Comprises Ryzodeg® and NovoMix®.
3) Comprises Fiasp® and NovoRapid®.
4) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.
5) Comprises NovoSeven®, NovoEight®, Esperoct®, Refixia®, NovoThirteen® and Alhemo®.
6) Primarily Norditropin® and Sogroya®.
7) Primarily Vagifem® and Activelle®.

2030 ambitions	Performance highlights	Commercial execution	Financials	Cash flow and capital allocation	Outlook	R&D pipeline progress	Sustainability	Corporate Governance	Legal matters	Financial information

Financial report for the period 1 January 2026 to 30 September 2026	Page 30 of 35

Appendix 6: Sales IFRS reconciliation

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.